Drug intelligence / Profile preview

haemagglutinin-strain a(h1n1)

Development stage
Approved
Lead developer
Parent
Modality
Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
Administration
Intramuscular
01

Overview

Haemagglutinin-strain A(H1N1) is the hemagglutinin protein derived from the influenza A virus subtype H1N1. It is used as an active component in various inactivated influenza vaccines. Hemagglutinin (HA) is a surface glycoprotein of the influenza virus responsible for binding to host cell receptors containing sialic acid and mediating fusion between viral and endosomal membranes during infection initiation. The HA protein is highly immunogenic and serves as the primary antigen targeted by neutralizing antibodies following vaccination or natural infection. Vaccines containing this antigen are indicated for prevention of influenza caused by H1N1 strains[3][4][5][8]. The mechanism of action involves induction of an immune response against HA to prevent viral entry into host cells.

Brand names
afluira tetraagrifluflulaval tetrafluadfluad pediatricfluviralfluzonefluzone high-dose quadrivalentfluzone quadrivalentinfluvac tetra
02

Targets

HA (Hemagglutinin)

Beyond the preview

Go deeper on haemagglutinin-strain a(h1n1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on haemagglutinin-strain a(h1n1).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call